Grzegorz Ślifirski

Mr. Grzegorz Ślifirski

Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GŚGrzegorz Ślifirski
Grzegorz Ślifirski
MKMarek Król
Marek Król
JTJadwiga Turło
Jadwiga Turło
Serotonin modulates several physiological and cognitive pathways throughout the human body that affect emotions, memory, sleep, and thermal regulation. The complex nature of the serotonergic system and interactions with other neurochemical systems indicate that the development of depression may be mediated by various pathomechanisms, the common denominator of which is undoubtedly the disturbed transmission in central 5-HT synapses. Therefore, the deliberate pharmacological modulation of serotonergic transmission in the brain seems to be one of the most appropriate strategies for the search for new antidepressants. As discussed in this review, the serotonergic system offers great potential for the development of new antidepressant therapies based on the combination of SERT inhibition with different pharmacological activity towards the 5-HT system. The aim of this article is to summarize the search for new antidepressants in recent years, focusing primarily on the possibility of benefiting from interactions with various 5-HT receptors in the pharmacotherapy of depression.


Verified
Journal Article
Open access
PDF file
MKMarek Król
Marek Król
GŚGrzegorz Ślifirski
Grzegorz Ślifirski
JKJerzy Kleps
Jerzy Kleps
SUSzymon Ulenberg
Szymon Ulenberg
MBMariusz Belka
Mariusz Belka
FHFranciszek Herold
Franciszek Herold
Two series of novel 4-aryl-2H-pyrido[1,2-c]pyrimidine (6a–i) and 4-aryl-5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine (7a–i) derivatives were synthesized. The chemical structures of the new compounds were confirmed by 1H and 13C NMR spectroscopy and ESI-HRMS spectrometry. The affinities of all compounds for the 5-HT1A receptor and serotonin transporter protein (SERT) were determined by in vitro radioligand binding assays. The test compounds demonstrated very high binding affinities for the 5-HT1A receptor of all derivatives in the series (6a–i and 7a–i) and generally low binding affinities for the SERT protein, with the exception of compounds 6a and 7g. Extended affinity tests for the receptors D2, 5-HT2A, 5-HT6 and 5-HT7 were conducted with regard to selected compounds (6a, 7g, 6d and 7i). All four compounds demonstrated very high affinities for the D2 and 5-HT2A receptors. Compounds 6a and 7g also had high affinities for 5-HT7, while 6d and 7i held moderate affinities for this receptor. Compounds 6a and 7g were also tested in vivo to identify their functional activity profiles with regard to the 5-HT1A receptor, with 6a demonstrating the activity profile of a presynaptic agonist. Metabolic stability tests were also conducted for 6a and 6d.

1 March 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GŚGrzegorz Ślifirski
Grzegorz Ślifirski
MKMarek Krol
Marek Krol
JKJerzy Kleps
Jerzy Kleps
SUSzymon Ulenberg
Szymon Ulenberg
MBMariusz Belka
Mariusz Belka
FHFranciszek Herold
Franciszek Herold

1 October 2020 in Journal of Chromatography A
Verified
Journal Article
Closed access
SUSzymon Ulenberg
Szymon Ulenberg
PGPaweł Georgiev
Paweł Georgiev
MBMariusz Belka
Mariusz Belka
GŚGrzegorz Ślifirski
Grzegorz Ślifirski
MWMartyna Zofia Wrobel
Martyna Zofia Wrobel
TBTomasz Baczek
Tomasz Baczek

1 October 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GŚGrzegorz Ślifirski
Grzegorz Ślifirski
MKMarek Krol
Marek Krol
JKJerzy Kleps
Jerzy Kleps
PPPiotr Podsadni
Piotr Podsadni
MBMariusz Belka
Mariusz Belka
FHFranciszek Herold
Franciszek Herold